8-K: Canopy Growth Narrows Loss, Boosts Cannabis Revenue

Canopy Growth Corporation reported a significant reduction in net loss and improved free cash flow in Q1 FY2026, driven by strong Canada adult-use cannabis sales and cost efficiencies, despite a decline in gross margin and Storz & Bickel revenue.

Summary

• Consolidated net revenue increased 9% year-over-year to $72.1 million in Q1 FY2026.
• Net loss from continuing operations improved by 68% to $(41.5) million in Q1 FY2026, compared to $(129.2) million in Q1 FY2025.
• Free cash flow outflow decreased by 79% to $(11.6) million in Q1 FY2026, from $(55.7) million in Q1 FY2025.
• Adjusted EBITDA loss widened by 50% to $(7.9) million in Q1 FY2026, from $(5.3) million in Q1 FY2025.
• Consolidated gross margin decreased to 25% in Q1 FY2026, down from 35% in Q1 FY2025.
• Cannabis segment net revenue increased 24% year-over-year to $57.0 million.
• Canada adult-use cannabis net revenue surged 43% to $27.0 million, benefiting from increased distribution and strong demand for new products like Claybourne infused pre-roll joints.
• Storz & Bickel net revenue decreased 25% to $15.1 million.
• Achieved $17 million of the planned $20 million annualized savings target since March 1, 2025.
• Selling, General and Administrative (SG&A) expenses decreased 21% year-over-year.
• Cash and short-term investments increased to $144 million at June 30, 2025, from $131 million at March 31, 2025.
• Margaret Shan Atkins was appointed as a new independent director to the Board and a member of the audit committee, effective August 6, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While gross margins declined and Adjusted EBITDA loss widened, the significant improvements in net loss and free cash flow, coupled with strong cannabis revenue growth and effective cost control, indicate a positive trajectory towards financial stability. The new director appointment also strengthens governance. However, the continued Adjusted EBITDA loss and explicit 'going concern' risk temper overall optimism.

Positives

• Net loss from continuing operations significantly improved by 68% to $(41.5) million.
• Free cash flow outflow dramatically reduced by 79% to $(11.6) million, indicating improved cash management.
• Consolidated net revenue increased by 9% year-over-year.
• Canada adult-use cannabis net revenue grew by a strong 43% to $27.0 million, reflecting successful commercial strategy and product demand.
• Achieved $17 million of the $20 million annualized savings target, demonstrating effective cost control.
• SG&A expenses decreased by 21% year-over-year, contributing to operational efficiency.
• Cash and short-term investments increased to $144 million, strengthening liquidity.
• Appointment of Margaret Shan Atkins, an independent director with extensive experience in retail, consumer goods, and finance, enhances corporate governance.

Negatives

• Consolidated gross margin decreased significantly to 25% from 35%, primarily due to lower Storz & Bickel sales, reduced high-margin sales in Poland, and a shift to higher-cost manufactured cannabis products in Canada.
• Adjusted EBITDA loss widened by 50% to $(7.9) million, despite lower operating expenses.
• Storz & Bickel net revenue declined by 25% to $15.1 million, attributed to strong prior-year sales and consumer economic uncertainty.
• Cannabis gross margins decreased to 24% from 33% due to product mix shift and lower sales in high-margin markets.

Risks

• Uncertainty regarding the application of U.S. state and federal law to cannabis and hemp products and the scope of regulatory agencies.
• Potential for impairment losses, including write-downs of intangible assets and goodwill.
• Ability to refinance debt and comply with covenants in debt facilities and instruments.
• Risks related to the Company's strategy to accelerate entry into the U.S. cannabis market through Canopy USA, including its ability to capitalize on growth opportunities.
• Uncertainty regarding the timing and occurrence of the final tranche closing for the acquisition of Jetty.
• Risks associated with the issuance of additional common shares to satisfy deferred and/or option exercise payments for Wana and Jetty.
• Risks related to the Huneeus 2017 Irrevocable Trust's potential significant ownership and influence over Canopy USA.
• Risks in the event that Acreage Holdings, Inc. cannot satisfy its debt obligations.
• Volatility and/or degradation of general economic, market, industry, or business conditions, including impacts of inflation, interest rates, and trade policy.
• Risks relating to the evolving regulatory landscape in the United States and current/future operations in emerging markets.
• Compliance with applicable environmental, economic, health and safety, energy, and other policies and regulations, particularly health concerns with vaping and cannabis products.
• Uncertainty regarding future product development and changes in regulatory requirements.
• Reliance on licenses issued by and contractual arrangements with various governmental authorities.
• Inherent uncertainty associated with financial projections and future levels of revenues.
• Risks related to third-party manufacturing and transportation.
• Exposure to risks of an agricultural business, including wholesale price volatility and variable product quality.
• Risks relating to inventory write-downs.
• Risks associated with jointly owned investments.
• Ability to manage disruptions in credit markets or changes to credit ratings.
• Risks related to the integration of acquired businesses.
• Uncertainty regarding the timing and manner of cannabis legalization in the United States.
• Counterparty risks and liquidity risks impacting the ability to obtain loans and credit facilities.
• Potential effects of judicial, regulatory, or other proceedings, litigation, or investigations.
• Risks associated with divestment and restructuring.
• Anticipated effects of actions by third parties such as competitors, activist investors, or regulatory authorities.
• Risks related to stock exchange restrictions and the protection/enforcement of intellectual property rights.
• The Company's ability to continue as a going concern.

Future Outlook

The Company expects to continue building momentum in its Canada adult-use cannabis business by expanding retail distribution and focusing on high-demand product segments through fiscal year 2026. Supply chain improvements are anticipated to increase cannabis supply and consistency in margin-accretive European markets in the second half of FY2026. Management also expects to improve cannabis gross margins in the second half of FY2026 through automation technology deployment, increased pre-rolled joint production capacity, and continued pursuit of margin-accretive bulk cannabis sales in Canada and Europe. Storz & Bickel plans to launch a new vaporizer in the second half of calendar year 2025, which is expected to generate strong consumer interest. The Company aims to strengthen its financial position and ultimately achieve Adjusted EBITDA profitability through continued financial discipline and business simplification.

Management Comments

• "We delivered strong top line growth in the first quarter of fiscal 2026, led by momentum in our Canada adult-use cannabis business where we're gaining share in high-demand categories, and steady performance across our global medical cannabis business. This reflects the early impact of our focused commercial strategy and a more disciplined execution. I'm confident we can continue to build on this momentum through the remainder of the year." Luc Mongeau, Chief Executive Officer
• "Our financial discipline has already delivered meaningful operating expense reductions, and we see further opportunity to simplify and focus the business. Improving gross margin remains a key priority while maintaining topline performance in all areas of the business. These actions are critical to strengthening our financial position through the remainder of fiscal 2026 and ultimately achieving Adjusted EBITDA profitability." Tom Stewart, Interim Chief Financial Officer

Industry Context

The cannabis industry continues to navigate evolving regulatory landscapes and competitive pressures. Canopy Growth's strong growth in Canada's adult-use market, particularly in manufactured products like infused pre-rolls, indicates a successful adaptation to consumer preferences and market trends within a maturing recreational segment. The decline in Storz & Bickel's vaporizer sales, however, suggests broader consumer economic uncertainty impacting discretionary spending on devices, or increased competition in the vaporizer market. The focus on cost efficiencies and supply chain improvements aligns with a broader industry trend towards profitability and operational sustainability as companies mature beyond initial growth phases.

Comparison to Industry Standards

• The 43% year-over-year growth in Canada adult-use cannabis net revenue is robust, indicating market share gains in a competitive landscape. For instance, while specific comparable company data for Q1 FY2026 is not provided, this growth rate outpaces the general market growth observed in some Canadian provinces, suggesting effective distribution and product innovation, particularly with Claybourne infused pre-roll joints, which saw a 58% sequential sales increase.
• The decline in gross margin to 25% (from 35%) is a concern, especially when compared to some more established consumer goods companies or even some cannabis peers that have achieved higher gross margins through scale and vertical integration. The shift to higher-cost manufactured products like infused pre-rolls, while driving revenue, impacts profitability, a common challenge for companies expanding product portfolios.
• The significant improvement in free cash flow outflow (79% reduction) and net loss (68% reduction) demonstrates strong progress in operational efficiency and cash management, which is critical in the capital-intensive cannabis sector. This contrasts with many early-stage cannabis companies that continue to burn significant cash, positioning Canopy Growth more favorably in terms of financial discipline, despite the widening Adjusted EBITDA loss.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The significant reduction in net loss and free cash flow outflow, coupled with strong cannabis revenue growth, could be viewed positively as indicators of improving financial health and operational efficiency, potentially leading to increased shareholder confidence. However, the widening Adjusted EBITDA loss and the explicit 'going concern' risk remain concerns.
• **Employees**: The mention of headcount reductions at Storz & Bickel indicates potential negative impacts on employees in that segment, while the focus on automation technology and increased production capacity might shift labor needs in other areas.
• **Customers**: Increased distribution and strong consumer demand for new products, particularly in Canada adult-use cannabis, suggest positive engagement and satisfaction among customers. The planned launch of a new Storz & Bickel vaporizer aims to further engage customers.
• **Suppliers**: Supply chain improvements in international markets are expected to increase cannabis supply, which could imply more consistent demand for certain suppliers, particularly in European markets.
• **Creditors**: The improvement in free cash flow and the increase in cash and short-term investments could be viewed favorably by creditors, indicating improved liquidity and ability to manage debt obligations, although the company's ability to refinance debt and comply with covenants remains a risk factor.

Next Steps

• Maintain commercial momentum in the adult-use cannabis business, focusing on expanding retail distribution and executing against high-demand product segments through FY2026.
• Implement supply chain improvements in international markets to increase cannabis supply and consistency in European markets in the second half of FY2026.
• Deploy automation technology and increase pre-rolled joint production capacity to improve cannabis gross margins in the second half of FY2026.
• Continue pursuing margin-accretive bulk cannabis sales in Canada and Europe.
• Launch a new Storz & Bickel vaporizer in the second half of calendar year 2025.
• Continue to simplify and focus the business to achieve Adjusted EBITDA profitability.

Key Dates

Recommendation

While Canopy Growth demonstrated significant improvements in net loss and free cash flow, alongside robust growth in its core Canada adult-use cannabis segment and effective cost control, the widening Adjusted EBITDA loss and a notable decline in gross margins present ongoing challenges. The explicit mention of 'ability to continue as a going concern' as a risk factor is a serious consideration for investors. The company is moving in the right direction operationally, but the path to sustained profitability and financial stability is still uncertain. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive operational momentum while remaining cautious due to persistent profitability issues and inherent industry risks.

Keywords

Cannabis, Marijuana, Vaporizers, SEC Filing, Financial Results, Earnings, Cannabis Revenue, Adult-Use Cannabis, Medical Cannabis, Storz & Bickel, Adjusted EBITDA, Free Cash Flow, Corporate Governance, Director Appointment, Cost Savings, Canada Cannabis, Infused Pre-Rolls